UVC radiation therapy for chronic lymphocytic leukemia
AssigneeClemson University
InventorsLyndon L. Larcom, Amy Tuck, Samuel Smith
Life of this patent
Estimating the term…
Loading patent…
AssigneeClemson University
InventorsLyndon L. Larcom, Amy Tuck, Samuel Smith
Estimating the term…
Lymphocytes from chronic lymphocytic leukemia (CLL) patients have been found to be readily killed by ultra-violet light-C (UVC) radiation. Cells from healthy donors were minimally affected by doses of UVC 10 times higher than those which caused dramatic drops in the metabolism of CLL cells and eventual death. Irradiated cells from CLL patients and from healthy individuals all demonstrated a number of single strand DNA breaks and alkali-labile sites compared to unirradiated control cells. The extent of DNA damage to both healthy and CLL cells is dose dependent. However, the CLL cells demonstrated more extensive DNA fragmentation and an inability to undergo self-repair. The heightened sensitivity to UVC radiation of lymphocytes from CLL patients is used to provide an excorporeal treatment of CLL lymphocytes followed by the re-introduction of the treated lymphocytes to the patient.
A method for reducing the population of lymphocytes from chronic lymphocytic leukemia patients comprising:
A process of killing lymphocytes from a patient having chronic lymphocytic leukemia comprising the steps of:
A method for reducing the population of accumulated B-lymphocytes in the G0 stage of a cell cycle from a chronic lymphocytic leukemia patient comprising the steps of:
Dependencies are inferred from the claim text.